title: Nevirapine-based regimens in routine clinical settings: results from a large Italian cohort of HIV-1 infected adults.
abstract: We assessed the safety and efficacy of different nevirapine-based regimens in patients starting this drug in a large cohort of Caucasian subjects during the 1999-2007 periods.
  
  
  METHODS
  A retrospective database review of all patients receiving nevirapine was performed; clinical, biochemical (hepatic and metabolic profiles), immuno-virological parameters were evaluated in the overall population and in different subgroups (according to gender, therapy-experience and HBV/HCV co-infection). We determined risk factors related to dyslipidemia development and to nevirapine interruption within 1 year.
  
  
  RESULTS
  We evaluated 277 patients; 58 (20.9%) were naïve, 180 (65%) females and 137 (49.5%) HBV/HCV co-infected. After 48 weeks, 73.6% patients continued antiretroviral regimens. Among these, nevirapine showed little hepatic and metabolic impact, as well as good immuno-virological outcome despite sex, drug experience and co-infection. Factors related to development of dyslipidemia were higher in total cholesterol, female gender with high CD4 count and male gender with low CD4 count (p<0.05). Factors related to discontinue nevirapine were age and HBV/HCV co-infection (p<0.05).
  
  
  CONCLUSIONS
  We observed a high rate of discontinuation probably because of the special composition of our population (huge proportion of women and co-infected individuals). Nevertheless, nevirapine was a well-tolerated drug with a favorable impact on hepatic, metabolic and immuno-virological parameters in all the analyzed subgroups.
authors: Department of Internal Medicine and Infectious Diseases, "San Martino" Hospital, Genoa, Italy.
authors: Raffaella
authors: R
authors: Rosso
authors: Roberto
authors: R
authors: Rossotti
authors: Antonio
authors: A
authors: Di Biagio
authors: Laura
authors: L
authors: Nicolini
authors: Fulvio
authors: F
authors: Adorni
authors: Anna
authors: A
authors: Orani
authors: Claudio
authors: C
authors: Viscoli
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D002784:Cholesterol / Q000097:blood; D015331:Cohort Studies; D016208:Databases, Factual; D050171:Dyslipidemias / Q000209:etiology*; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D006509:Hepatitis B / Q000150:complications; D006526:Hepatitis C / Q000150:complications; D006801:Humans; D007558:Italy; D008297:Male; D008875:Middle Aged; D019829:Nevirapine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012189:Retrospective Studies; D012307:Risk Factors; D012737:Sex Factors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D019380:Anti-HIV Agents; D002784:Cholesterol; D019829:Nevirapine